MedTrace Logo

Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients

NCT04497649 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-12-03

No results posted yet for this study

Summary

efficacy and safety of Sofosbuvir containing regimens in treatment of COVID-19 Egyptian patients,

Conditions

  • Covid19

Interventions

DRUG

Sofosbuvir

Sofosbuvir once daily

DRUG

Daclatasvir

daclatasuvir once daily

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Marwa Salama, Lecturer · Tanta University - Faculty of Medicine

  • sherief Abd-Elsalam, ass. Prof. · Tanta University Faculty of medicine

  • Ahmed Cordie, lecturer · Cairo University

  • Gamal Esmat, Professor · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2021-04-01
Completion
2021-04-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04497649 on ClinicalTrials.gov